The off-target effects of torcetrapib

Endocrinology. 2009 May;150(5):2024-6. doi: 10.1210/en.2009-0136.
No abstract available

Publication types

  • Evaluation Study
  • Comment

MeSH terms

  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / pharmacology
  • Blood Pressure / drug effects
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors
  • Cholesterol, HDL / metabolism
  • Drug Delivery Systems* / adverse effects
  • Gene Expression Regulation / drug effects
  • Humans
  • Hyperaldosteronism / chemically induced
  • Hyperaldosteronism / mortality
  • Quinolines / administration & dosage
  • Quinolines / adverse effects*
  • Quinolines / pharmacology*
  • Water-Electrolyte Imbalance / chemically induced
  • Water-Electrolyte Imbalance / mortality

Substances

  • Anticholesteremic Agents
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Quinolines
  • torcetrapib